Ignite Creation Date:
2024-05-06 @ 7:17 AM
Last Modification Date:
2024-10-26 @ 11:47 AM
Study NCT ID:
NCT02507947
Status:
WITHDRAWN
Last Update Posted:
2018-07-09
First Post:
2015-07-23
Brief Title:
SPECTAmel Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Organization:
European Organisation for Research and Treatment of Cancer - EORTC
Study Overview
Official Title:
SPECTAmel Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access
Status:
WITHDRAWN
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study closed
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
SPECTAmel is a standardized quality-assured molecular screening platform for tumor characterization and storage of human biological material HBM for the purpose of integrating new biomarkers into clinical trials and optimizing access of patients to therapeutic biomarker-driven clinical trials HBM and clinicalpathological data are collected from consenting patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None